Ramucirumab plus Erlotinib as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR exon 21 L858R mutation: A multicenter retrospective observational cohort study in Japan (REAL-SPEED)
Not Applicable
- Conditions
- Advanced or recurrent non-small cell lung cancer harboring EGFR exon21 L858R mutation
- Registration Number
- JPRN-UMIN000052047
- Lead Sponsor
- Teikyo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Active double cancers* *Double cancers are synchronous double cancers and metachronous double cancers with a disease-free interval of <3 years, and lesions in carcinoma in situ or mucosal equivalent that are considered cured by local treatment should not be included in active double cancers.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to treatment failure (TTF)
- Secondary Outcome Measures
Name Time Method Overall survival (OS Progression-free survival (PFS) Progression-free survival 2 (PFS2) Time to discontinuation of any EGFR-TKI (TD-TKI) Time to failure of strategy (TFS) Objective response rate (ORR) Disease control rate (DCR) Safety